Nasal switches ring up incremental sales

Chattem’s launch of the first nasal corticosteroid onto OTC shelves represented the most significant success story in the cough-cold-allergy space in the past year. 

Want to Read More?

This content is available only to registered users. Log in to read the rest of this article or create a free account.

Login or Register to post a comment.